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A B S T R A C T
BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the
standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU
shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We
conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and
FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607,
FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and
59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement,
previous treatments, response before ASCT, and overall conditioning intensity were well balanced between
BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P < .001),
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Sorror score ≥3 (BEAM = 15% versus FEAM = 10%, P = .017), and radiotherapy use (BEAM = 18% versus
FEAM = 10%, P < .001). FEAM conditioning resulted in higher rates of gastrointestinal and infectious toxicities,
including severe oral mucositis grade ≥3 (BEAM = 31% versus FEAM = 44%, P < .001), and sepsis from
Gram-negative bacteria (mean isolates/patient: BEAM = .1 versus FEAM = .19, P < .001). Response status at day
100 post-ASCT (overall response: BEAM = 91% versus FEAM = 88%, P = .42), 2-year overall survival (83.9%; 95%
confidence interval [CI], 81.5% to 86.1%) and progression-free survival (70.3%; 95% CI, 67.4% to 73.1%) were
not different in the two groups. Mortality from infection was higher in the FEAM group (subhazard ratio,
1.99; 95% CI, 1.02 to 3.88; P = .04). BEAM and FEAM do not appear different in terms of survival and disease
control. However, due to concerns of higher toxicity, fotemustine substitution in BEAM does not seem justified,
if not for easier supply.
© 2018 American Society for Blood and Marrow Transplantation.
INTRODUCTION
The first series of patients transplanted with autologous
marrow for lymphomas was reported in 1978, using the BACT
(carmustine [bis-chloroethylnitrosourea (BCNU)]-cytarabine-
cyclophosphamide-thioguanine) regimen [1]. Many variants
were derived from the same chemotherapy backbone, among
which was the BEAM (BCNU-etoposide-cytarabine-melphalan)
regimen, first reported in 1986 [2].
The BEAM regimen had strong conceptual points favour-
ing its widespread application: it used readily available
well-known drugs; it appeared highly effective in relapsed
and refractory Hodgkin lymphoma (HL) [3] and non-Hodgkin
lymphoma (NHL) [4], while also having acceptable
extrahematologic toxicities. These consisted mostly in severe
mucositis, chemotherapy-induced nausea and vomiting, di-
arrhea, hepatotoxicity, and nephrotoxicity [4-7]. Moreover,
noninfective toxic pulmonary complications were reported
in BCNU-containing regimens, involving 16% to 64% of pa-
tients among different studies [8]. Despite these limitations,
in the last 40 years there have been few, if any, real alterna-
tives to challenge BEAM as the standard conditioning regimen
for lymphomas undergoing autologous stem cell transplan-
tation (ASCT) [9].
Unexpectedly, though, after 2010 the oncological and
hematological community faced the novel and unpredicted
issue of shortage of some essential chemotherapy drugs,
among which was BCNU. Physicians were thus forced to
change their standards for those regimens in which a com-
ponent was no longer available: a common solution was to
replace the missing drug with a similar substitute mole-
cule, trusting that the modified regimen would lead to similar
results in terms of efficacy and toxicity [10].
Although reasonable, such an approach was prone to dan-
gerous risks: a national U.S. survey in 2013 showed that use
of surrogate drugs could have induced medication errors and
increased unexpected toxicity [11]; reduced efficacy has also
been reported when substituting one component of a con-
solidated regimen with a “similar” agent [12].
BCNU shortage was reported in Italy in the same years
[13]: fotemustine, a third-generation nitrosourea with throm-
bocytopenia as main dose-limiting toxicity, was chosen as a
potential substitute. As it was developed for treatment of brain
tumors, fotemustine had been engineered as a molecule with
enhanced lipophilia, to ensure high cellular and central
nervous system penetration [14]. The first retrospective study
to test the fotemustine-substituted BEAM (FEAM) reported
promising results in 84 patients with HL and NHL: in this
series, the overall survival (OS), progression-free survival (PFS),
and nonrelapse mortality (NRM) at 2 years were 85%, 73%,
and 2.4%, respectively [15]. A prospective study focusing
on HL had been recently reported by the same authors, with
similar results [16]: in 122 patients, FEAM-conditioned ASCT
yielded a 2-year PFS of 73.8%; the 100-day treatment-
related mortality was 2.5%, in all cases attributable to
multiorgan failure secondary to sepsis from Gram-negative
bacteria.
These encouraging data, together with the persistent dif-
ficulties of supply for BCNU, contributed to the ever-increasing
fortune in Italy of FEAM conditioning, even if comparative
studies between fotemustine and BCNU, especially in the
context of ASCT, were missing.
The present study was therefore designed to fill this gap
and to compare the efficacy, safety, and toxicity of the BEAM
and FEAM regimens. We chose to consider data retrospec-
tively from the experience, already available to 18 Italian ASCT
units up to now, for several reasons. Although, theoretical-
ly, a randomized comparison would have been preferable, the
main reason for switching from BEAM to FEAM (ie, BCNU
shortage) would have threatened the feasibility of such a
study. Moreover, we reasoned that the purely logistic and
nonclinical choice of the treatment allocation between BEAM
and
FEAM would reduce the selection bias attributable to a
nonrandomized comparison. Finally, we needed to achieve
a prompt answer to concerns of toxicity regarding a widely
used treatment, and that appeared more easily met by using
retrospective data.
METHODS
An extended Methods section is reported in Supplementary Data.
This is a cohort multicenter retrospective study enrolling all consecu-
tive patients undergoing ASCT for lymphomas from January 1, 2008, to
December 31, 2015, conditioned with BEAM or FEAM regimen [4].
The study was approved by the institutional review board of the coor-
dinating center and of all participating centers. The primary study endpoint
was the frequency (intended as proportion of patients) of severe infec-
tious events (grade 3 or 4 according to Common Terminology Criteria for
Adverse Events [CTCAE] version 4.0) occurring in the first 100 days after trans-
plantation. The secondary endpoints were: the overall response rate evaluated
100 days after ASCT (defined according to standard lymphoma response cri-
teria [17]); OS, PFS, cumulative incidence of relapse (RI) and nonrelapse
mortality (NRM); engraftment of neutrophils (defined as the first of 3 con-
secutive days with a neutrophil count > 500 cells/μL) and platelets (defined
as the first of 3 consecutive days with unsupported platelets count ≥20,000
cells/μL); the frequency of severe adverse events of any type (grades 3 and
4 according to CTCAE version 4.0); and the frequency of mucositis accord-
ing to the World Health Organization criteria [18].
Severe infectious events (SIEs) were categorized as: SIE with microbio-
logical identification (SIEM+); severe event of presumed infectious origin but
without microbiological identification (SIEM–) (eg, pneumonia or neutro-
penic enterocolitis); and febrile neutropenia (FN) [19].
Treatment Protocols
Patients were treated with either the BEAM regimen [4], consisting of
BCNU (300 mg/m2 i.v., day − 7), etoposide (200 mg/m2 days − 6 to − 3),
cytarabine (400 mg/m2 days − 6 to − 3), and melphalan (140 mg/m2 day −2),
or the FEAM regimen, with substitution of BCNU with fotemustine 150 mg/m2
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i.v. days −7 and −6); variations in timing and fractionation of the drug doses
were allowed, provided that the cumulative dose was maintained.
Supportive Measures
Supportive measures were given per local policy and declared in a survey
among participating centers. In general, post-transplant granulocyte colony-
stimulating factor (Filgrastim in most cases) was started shortly after
reinfusion (day 3) and continued until neutrophil recovery; antimicrobial
prophylaxis consisted of oral fluconazole, ciprofloxacin or levofloxacin, and
acyclovir, started on day 0; fluconazole and fluoroquinolones were gener-
ally stopped at hematologic recovery or 1 month after reinfusion; acyclovir
was continued for 3 months after transplant. Cotrimoxazole was adminis-
tered for Pneumocystis jiroveci pneumonia prophylaxis from hematologic
recovery until 3 months after reinfusion (or when CD4 were ≥200/mm3). In
case of fever and absolute neutrophil count <.5 × 109/L, empiric broad-
spectrum i.v. antibiotics were administered (piperacillin/tazobactam in most
cases). Packed RBC and platelet transfusions were administered in case of
a hemoglobin level <80 g/L and platelet count 15,000 <109/L.
Statistical Considerations
We performed a power analysis to measure the minimum effect size of
the primary endpoint likely to be detected with our planned sample: basing
on an expected enrollment of 900 patients (BEAM = 600; FEAM = 300) and
considering an expected frequency of SIEs equal to 50%, and a type I error
set at .05, we estimated that such sample would allow to identify a 1.5-
fold increased odds of SIEs in FEAM with a power of .805 [20].
Statistical tests were used to compare baseline characteristics or outcome
measures between the BEAM and FEAM groups. OS and PFS were com-
puted using the Kaplan-Meier method. Univariate and multivariate analyses
were performed using the Cox proportional hazards method. The cumula-
tive incidence method was applied to compute the RI, NRM, and cause-
specific mortality in a competing risks setting. Predictive analyses for RI and
NRM were based on the proportional hazards model for subdistribution of
competing risk. Univariate and multivariate analyses were performed using
Gray’s test and the proportional subdistribution hazard regression model
developed by Fine and Gray [21].
All tests were 2 sided. The type I error rate was fixed at .05. Analyses
were performed using Stata 12.0 (StataCorp, College Station, Texas).
RESULTS
Baseline Characteristics
A total of 1038 patients (607 treated with BEAM and 431
treated with FEAM) were included in the study, enrolled
from 18 Italian centers (Table 1). There were no differences
in the baseline characteristics of the patients with respect to
age (53.1 and 52.7 years in the BEAM and FEAM groups, re-
spectively; P = .51), sex or disease distribution: the main
indication for ASCT in both groups was aggressive NHL
(BEAM 57% versus FEAM 61.7%), with diffuse large B cell
lymphoma representing the largest disease category (BEAM
30.1% versus FEAM 30.4%), followed by mantle cell lym-
phoma (BEAM 12.5% versus FEAM 16%); the remainder were
HL (BEAM 27% versus FEAM 26.5%) and indolent NHL (BEAM
15.5% versus FEAM 11.6%). Also, disease characteristics at di-
agnosis were similar between the 2 groups: most patients
were in advanced stage (BEAM 80.7% versus FEAM 77.7%) and
about one-third had bone marrow involvement (BEAM 33.6%
versus FEAM 34.6%); central nervous system involvement at
diagnosis was rare (BEAM 1.7% versus FEAM 3.3%).
The therapeutic history of the patients did not differ in the
2 groups with respect to the number of previous chemother-
apy courses (median 2 lines of therapy for both groups);
however, radiotherapy use was more frequent in the BEAM
group, both at any site (BEAM 18.1% versus FEAM 9.7%,
P < .001) and to the mediastinal region (BEAM 8.4% versus
FEAM 2.1%, P < .001). The rate of refractoriness to first-line
treatment was not different in the 2 groups (BEAM 14.8%
versus FEAM 13.9%), but there were more complete re-
sponses (CRs) recorded in the BEAM group (BEAM 60.8%
versus FEAM 50.3%, P = .001); likewise, overall response rate
before transplantation was similar in both groups (BEAM
92.7% versus FEAM 91%), but marginally more patients in the
BEAM group accessed to transplant with a CR (BEAM
65.2% versus FEAM 59.2%, P = .05). However, in the patients
evaluable for metabolic response before ASCT (BEAM = 471;
FEAM = 288), the rate of positron emission tomography posi-
tivity was not different in the 2 groups (BEAM 29.3% versus
FEAM 33%).
The comorbidity burden measured by hematopoietic cell
transplantation specific comorbidity index was signifi-
cantly higher in BEAM-conditioned patients (hematopoietic
cell transplantation specific comorbidity index ≥3: BEAM 15.3%
versus FEAM 10.1%, P = .02), as it was the rate of pulmonary
comorbidity (BEAM 19.5% versus FEAM 7.8%, P < .001). The
time frame of ASCT was not the same in the 2 groups, with
2011 the median year of transplantation for BEAM patients
and 2013 for FEAM patients. Overall dose intensity was similar
for BEAM and FEAM conditioning (ratio ≥90% between de-
livered and standard dose: BEAM 80.7% versus FEAM 80.9%),
as it was the addition of the anti-CD20 antibody rituximab
(BEAM 5.3% versus FEAM 7.4%). The number of reinfused
CD34+ cells × 106/kg was slightly higher in the FEAM group
(median 5.5 versus 5.3, P = .045).
Toxicities
Toxicities between 2 groups are summarized in Table 2.
FEAM patients had a higher gastrointestinal toxicity, as
shown by a higher rate of grade ≥3 mucositis (BEAM 31%
versus FEAM 44%, P < .001), grade ≥3 nausea and vomiting
(BEAM 12% versus FEAM 17%, P = .03), and grade ≥3 (BEAM
21% versus FEAM 28%, P = .007) and ≥4 (BEAM 2.4% versus
FEAM 5%, P = .03) diarrhea. No other statistically significant
extrahematological toxicities emerged (Table 2).
Overall SIEs (by definition of grade ≥3) did not differ
between BEAM and FEAM patients (BEAM 71% versus FEAM
71%, P = .94), but grade ≥4 SIEs (BEAM 5% versus FEAM 11%,
P < .001) were higher in the FEAM group. In detail, in the FEAM
group there were more grade ≥4 FN events (BEAM 1.5% versus
FEAM 6.3%, P < .001) and a higher rate of grade ≥3 and ≥4
SIEM+ (BEAM 30% versus FEAM 36%, P = .05; BEAM 2.6% versus
FEAM 5.6%, P = .006). Among SIEM+, the FEAM group had
higher incidence of infections with Gram-negative bacteria
(mean isolates/patient: BEAM .10 versus FEAM .19, P < .001)
or fungi (mean isolates/patient: BEAM .015 versus FEAM .039,
P = .01) (Table 3).
Neutrophil engrafment was similar between the 2 groups,
but there was a delayed median platelet engrafment in FEAM
patients (BEAM 12 days versus FEAM 13 days, P < .001) with
higher need of platelet transfusions. Furthermore, hospital
stay (BEAM 21 days versus FEAM 23 days, P < .001) and need
of total parenteral nutrition were higher in the FEAM group
(BEAM 52% versus FEAM 64%, P < .001) (Table 3).
Outcome
Disease assessment at day 100 did not show any differ-
ence between the FEAM and BEAM groups (CR + partial
response: BEAM 91% versus FEAM 88%, P = .42). Further-
more, among CR patients, the rate of acquired CR (ie, patients
achieving post-transplant CR from pretransplant partial re-
sponse or less) was similar (BEAM 22.6% versus FEAM 23.7%).
Early death rate (for any cause, at day 100) was slightly higher
in the FEAM group (BEAM 3.5% versus FEAM 5.3%, P = .14)
without reaching statistical significance.
OS and PFS at 2 years in the whole cohort were 83.9% (95%
confidence interval [CI], 81.5% to 86.1%) and 70.3% (95% CI,
67.4% to 73.1%), respectively, without significant differences
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between the BEAM and the FEAM groups (Figure 1A,B).
Median follow-up was 42 months for both groups, and it was
longer for BEAM-treated patients (BEAM 50 months versus
FEAM 34 months, P < .001).
The cumulative RI (BEAM 18.4% versus FEAM 20.7%, P = .49)
and NRM (BEAM 2.6% versus FEAM 3.8%, P = .27) at 1 year did
not differ between the 2 groups (Figure 1C,D). Main death
causes in the whole cohort were lymphoma relapse or
Table 1
Basal Characteristics of the Enrolled Patients
Basal characteristics BEAM FEAM P Value
Evaluable patients n = 607 n = 431
Female 244 (40.2%) 169 (39.2) .75
Age, y 53.1 (16.5–79.5) 52.7 (17.2–77.8) .51
Disease n = 607 n = 431 .16*
Hodgkin lymphoma 164 (27.0) 114 (26.5)
Indolent NHL 94 (15.5) 50 (11.6)
Aggressive NHL 346 (57.0) 266 (61.7)
DLBCL 183 (30.1) 131 (30.4)
MCL 76 (12.5) 69 (16.0)
PTCL 52 (8.6) 39 (9.0)
Other 35 (5.8) 27 (6.3)
Disease characteristics at diagnosis n = 607 n = 431
Advanced stage (Ann Arbor stage III–IV) 490 (80.7) 335 (77.7) .24
B symptoms 235 (38.7) 157 (36.4) .45
BM involvement 204 (33.6) 149 (34.6) .75
CNS involvement 10 (1.7) 14 (3.3) .09
Pretransplant evaluation
Sorror score n = 603 n = 424 .017†‡
0 372 (61.7) 290 (68.4)
1–2 139 (23.1) 91 (21.5)
≥3 92 (15.3) 43 (10.1)
Lung comorbidity n = 603 n = 424 <.001§
Mild 66 (11.0) 30 (7.1)
Moderate-severe 51 (8.5) 3 (.7)
Therapeutic history n = 607 n = 431
Median previous chemotherapy courses 2 2 .43
Line of treatment n = 607 n = 431
Upfront ASCT (first line) 180 (29.7) 121 (28.1) .58‖
After salvage (second line) 339 (55.9) 242 (56.2)
After ≥3 lines of treatment 88 (14.5) 68 (15.8)
Radiotherapy before transplant n = 607 n = 431
Yes, any site 110 (18.1) 42 (9.7) <.001†
Mediastinal 51 (8.4) 12 (2.8) <.001†
Response to first line: n = 607 n = 431 .70¶
CR 369 (60.8) 217 (50.3)
PR 147 (24.2) 152 (35.3)
RD 90 (14.8) 60 (13.9)
Response before ASCT: n = 607 n = 431 .55¶
CR 396 (65.2) 255 (59.2)
PR 167 (27.5) 137 (31.8)
RD 41 (6.8) 33 (7.7)
ND 3 (.5) 6 (1.4)
Metabolic response before ASCT n = 471 n = 288
PET positive 138 (29.3) 95 (33.0) .29
Interval diagnosis n = 607 n = 431
Transplant, mo 13.0 (2–223) 13.5 (2.8–185) .80
Conditioning and transplant n = 607 n = 431
Median year of transplant 2011 2013 <.001‡
Full dose (≥90% delivered/standard) n = 471 n = 288
BCNU/fotemustine 476 (79.1) 374 (87) .001‡
Etoposide 490 (81.4) 380 (88.6) .002‡
Cytarabine 498 (82.7) 350 (81.6) .64
Melphalan 497 (82.6) 368 (85.6) .17
Overall 486 (80.7) 347 (80.9) .95
Rituximab addition to conditioning regimen n = 607 n = 431
Yes 32 (5.3) 32 (7.4) .16
Stem cell source n = 607 n = 431
Peripheral blood 598 (98.5) 430 (99.8) .05
Reinfused CD34+ × 106/kg 5.3 (1.1–22) 5.5 (2.0–27) .045‡
Data are presented as n (%) or median (range).
DLBCL indicates diffuse large B cell lymphoma; MCL, mantle cell lymphoma; PTCL, peripheral T cell lymphoma; BM, bone marrow; CNS, central nervous system;
PR, partial response; RD, resistant disease; ND, not done; PET, positron emission tomography.
* Comparison among major disease categories (HL, indolent NHL, aggressive NHL).
† Statistical significance <.05.
‡ Comparison between Sorror score <3 versus ≥3.
§ Comparison between no lung comorbidity versus mild + moderate + severe.
‖ Comparison between upfront ASCT versus after ≥2 lines of treatment.
¶ Comparison between CR + PR versus RD.
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progression in 138 patients, infection in 34, other treatment-
related causes in 35, secondary malignancy in 8, and other
or unknown cause in 11. There were no differences in all death
causes between the 2 groups, but mortality from infection
was significantly higher in the FEAM group (subhazard ratio,
1.99; 95% CI, 1.02 to 3.88; P = .04).
Time-dependent outcomes were also evaluated accord-
ing to major diagnostic categories (Supplementary Figures
S1–S3): when the 2 conditioning regimens were compared
within aggressive NHL, indolent NHL, and HL, there was no
significant difference for OS, PFS, RI, and NRM (Supplementary
Figure S2). However, there was a trend for a worse outcome
of the FEAM group in PFS (hazard ratio, 1.44; 95% CI, .96 to
2.16; P = .08) and RI (hazard ratio, 1.50; 95% CI, 1.00 to 2.27;
P = .051) (Figure S2B,C) in HL patients.
Multivariate analyses (MVAs) for OS and PFS confirmed
the negative roles of already known poor prognostic factors,
such as older age, an increasing treatment burden, and sub-
optimal quality of response before transplant (see Table 4).
Interestingly, the category of aggressive NHL was a poor in-
dependent predictor for OS but not for PFS; conversely, bone
marrow involvement at diagnosis, primary refractory pa-
tients, a reduced BCNU/fotemustine dose, and transplantation
in a FEAM-oriented center (BEAM/FEAM ratio <25%) emerged
as independent factors for PFS but not for OS.
The factors independently associated with a higher relapse
occurrence faithfully reproduced those seen for PFS, with the
exception of age. Finally, for NRM, the category of HL emerged
as a strong protective factor, together with CR before ASCT
and more recent time of transplantation; conversely, ASCT
after 2 lines of treatment and use of FEAM conditioning was
independently associated with worse NRM.
DISCUSSION
Our results suggest a comparable efficacy of FEAM and
BEAM conditioning in terms of survival and disease control
for lymphoma patients treated with high-dose chemother-
apy and ASCT. However, we also observed higher rates of
severe gastrointestinal toxicities and of infectious events
(mainly from Gram-negative bacteria) in patients trans-
planted after FEAM.
The BEAM chemotherapy has become the standard con-
ditioning regimen for lymphoproliferative diseases in the last
decades. In fact, a large retrospective study from the Center
for International Blood and Marrow Transplant Research
reports BEAM as increasingly used in the last 20 years, from
13.4% of all conditionings regimens in 1995 to 1999 to 64.1%
in 2005 to 2008, with cyclophosphamide, BCNU, and VP-16,
busulfan, cyclophosphamide, and total body irradiation–
based regimens as main alternatives [22].
A known concern related to BCNU is the development of
pulmonary fibrosis, which has been reported especially
Table 2
Main Extra-Hematological Toxicities According to CTCAE version 4.0
Toxicity BEAM FEAM P Value
Mucositis (World Health
Organization scale)
n = 591 n = 388
Grade 1 16.9% 9.3%
Grade 2 34.5% 23.7%
Grade 3 21.1% 34.8% <.001*
Grade 4 9.8% 9.0% .68
Nausea and vomiting (CTCAE 4.0) n = 591 n = 387
Grade 3 10.7% 16.1% .03*
Grade 4 1.5% 1.0% .58
Diarrhea (CTCAE 4.0) n = 591 n = 403
Grade 3 18.4% 23.3% .007*
Grade 4 2.4% 5.0% .03*
Other toxicities (CTCAE 4.0) n = 607 n = 431
Pulmonary (with grade ≥3) .7% .7% 1
Renal (with grade ≥3) 1.3% .7% .38
Hepatic (with grade ≥3) 2.0% 3.0% .31
Cardiac (with grade ≥3) 3.1% 1.6% .16
Cutaneous (with grade ≥3) .7% 1.2% .5
Other GI (with grade ≥3) 1.2% 1.2% 1
Neurological (with grade ≥3) .5% .5% 1
Vascular (with grade ≥3) .2% .7% .31
Other (with grade ≥3) .8% 1.2% .75
All toxicities, excluding infectious
and major GI (with grade ≥3)
9.2% 9.5% .88
GI indicates gastrointestinal.
* Statistical significance <.05.
Table 3
Transplant Outcomes in the First 100 Days after Reinfusion
BEAM FEAM P Value
Infectious events
FN n = 607 n = 431
Grade 3 45.1% 40.8% .86*
Grade 4 1.5% 6.3% <.001†‡
Grade 5 .16% .23%
Mean number of episodes .57 .54 .86
Without microbiological
identification
n = 607 n = 431
Grade 3 8.2% 8.6% .97*
Grade 4 1.7% 1.4% .81†
Grade 5 .16% 0%
Mean number of episodes .10 .11 .99
With microbiological
identification
n = 607 n = 431
Grade 3 27.4% 29.7% .05*†
Grade 4 2.6% 5.6% .006†‡
Grade 5 0% .46%
Mean number of isolates .34 .46 .02†
Gram-negative bacteria .097 .190 <.001†
Gram-positive bacteria .183 .165 .48
Fungal .015 .039 .01†




Any infectious event n = 607 n = 431
Grade 3 65.7% 59.2% .94*
Grade 4 4.9% 11.4% <.001†‡
Grade 5 .33% .70%
Mean number of episodes 1.02 1.10 .15
Engraftment
Days to neutrophils
> .5 × 103/L
n = 600 n = 429
Median (range) 10 (5–NR) 10 (6–NR) .09
Days to platelets > .5 × 103/L n = 553 n = 400
Median (range) 12 (3–NR) 13 (7–NR) <.001†
Transfusional support n = 595 n = 375
Median RBC units 2 2 .74
Median platelets units 2 3 .018†
Use of total parenteral
nutrition
n = 582 n = 365
Yes 52.2% 63.6% .001†
Need for intensive care unit n = 604 n = 430
Yes 1.5% 2.3% .32
Length of stay in hospital n = 602 n = 420
Median days (range) 21 (1–82) 23 (1–71) <.001†
Response at 100 days after
ASCT





* Comparison between experiencing ≥1 event of grade ≥3 versus not.
† Statistical significance <.05.
‡ Comparison between experiencing ≥1 event of grade ≥4 versus not.
§ Comparison between CR + PR versus RD.
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in regimens with higher BCNU doses (ie, cyclophospha-
mide, BCNU, and VP-16) than those scheduled in BEAM [22]
or when BCNU was combined with cyclophosphamide [8].
Thus, substitution of this component with other drugs, namely
thiotepa (TEAM) [23], lomustine (LEAM) [24], fotemustine
(FEAM) [15,16], and, most recently, bendamustine (BeEAM)
[25] has been proposed: all these alternatives to BEAM were
reported to be apparently equally or more effective in con-
trolling lymphoma and equally or less toxic than the original
regimen. However, such claims were inferred from compari-
sons with historical cohorts or studies, done in different
populations with different baseline risk factors, while no direct
comparison in the same cohort has been conducted so far.
A single exception, to our knowledge, is represented by an
ongoing prospective trial confronting the BeEAM regimen with
the BEAM regimens [26], the results of which are still
unavailable.
Despite belonging to the same drug class, one theoreti-
cal advantage of fotemustine over BCNU is the apparent lack
of pulmonary toxicity [27]: such a difference is explained by
the reduced interference with the glutathione system, whose
inhibition, driven by the carbamoylation activity of BCNU [28],
leads to unopposed production of reactive oxygen species and
lung fibrosis. In the 2 studies testing FEAM [15,16], no im-
mediate or late pulmonary toxicity was reported. In our data,
we observed a similarly low rate of pulmonary toxicity in both
groups: considering that BEAM-conditioned patients had more
lung comorbidities before ASCT and had a longer follow-up,
it is unlikely that BCNU causes a significantly higher pulmo-
nary toxicity.
Another compelling reason to search for alternatives to
BEAM was the shortage of several chemotherapy drugs, a
matter of the last decade [10]. As example, the shortage of
melphalan was routinely managed by substitution with cy-
clophosphamide (BEAC regimen); however, in 2016, 4 patients
with lymphoma treated with BEAC faced severe complica-
tions in a single stem cell transplant center in France. This
prompted a retrospective survey by European Group for Blood
and Marrow Transplantation on 383 patients treated with
BEAC, which were matched to 766 BEAM-treated patients.
Although the OS was similar (78% BEAC versus 77% BEAM),
cardiac deaths were 32% in the BEAC group compared with
23% in the BEAM group [29]; however, this difference was not
statistically significant, and the authors concluded that BEAC
was safe as a conditioning regimen.
For BCNU, the whole thing exploded from 2012 onward
[13], when increasing difficulties to find BCNU determined
a dramatic shift in the use of FEAM in Italy, forcing several
hematology units to switch to the new regimen, even if ev-
idence of equivalence was lacking. Moreover, BCNU shortage
made it impossible to promote a prospective comparison with
the new alternative; conversely, the growing experience with
fotemustine in Italy and the existence of good quality data-
bases in many Italian transplant centers, suggested the
feasibility and the opportunity of a retrospective compara-
tive analysis of FEAM and BEAM. Finally, given the absence
OS at 2y for FEAM: 83.7% (79.6% - 87%)
OS at 2y for BEAM: 84.1% (80.9% - 86.8%)
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Figure 1. (A) OS, (B) PFS, (C) cumulative RI, and (D) NRM, according to type of conditioning.
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of direct comparisons, and nonetheless, the increasing use
of fotemustine in Italy, such a study was ethically due, aimed
at least to exclude the possibility of a higher toxicity of the
FEAM new regimen compared with the standard.
In our study, we recognized several signals of increased
mucosal damage with FEAM: severe diarrhea resulting from
intestinal mucositis (grade ≥3: BEAM 20.8% versus FEAM
28.3%, P = .007) and oral mucositis (grade ≥3: BEAM 30.9%
versus FEAM 43.8%, P < .001) were in fact more frequent than
in the BEAM group. Such a difference persists if we stratify
our analysis by the attitude of centers (ie, those using
predominantly 1 of the 2 regimens and those switching
intermittently between the 2), making a measurement or per-
formance bias (due to fotemustine “novelty”) unlikely. The
reason for an increased mucotoxicity of fotemustine is not
obvious: both nitrosoureas do not usually cause mucositis if
used in monotherapy [14,30]; however, when used in com-
bination, the occurrence of severe oral mucositis is relevant,
with a reported occurrence of 42% [31] for BEAM and 15%
to 30% for FEAM [15,16]. While the major determinant for mu-
cositis severity is the type of chemotherapy regimen used [32],
yet there are no univocal pharmacological properties pre-
dicting its mucotoxicity. Drug distribution in mucosal tissues
has its role, given the established efficacy of cryotherapy in
preventing oral mucositis [33], by decreasing the exposure
of mucosal tissue to cytotoxic agents through vasoconstric-
tion. In this respect, the enhanced lipophilicity and tissue
penetration of fotemustine [14] may represent a drawback
and contribute to the increased mucotoxicity observed with
FEAM.
Mucositis is a complex phenomenon, originated by
DNA damage induced by chemo- or radiotherapy, in which
however proinflammatory cytokines play an important
role in boosting local injury. In this respect, the new concept
of “febrile mucositis” has emerged, highlighting the fact
that chemotherapy-induced fever may also result from the
inflammation arising in the context of mucositis, and not
just from gut-derived bacteremia [34]. Thus, a significant pro-
portion of prior labeled FNs may represent epiphenomena
of aseptic mucosal inflammation, carrying a different prog-
nosis and requiring different treatments. In our study, we
found a similar occurrence of SIEs in patients treated with
BEAM or FEAM. However, the rate of very severe FN (grade
≥4: BEAM 1.5% versus FEAM 6.3%) and SIEM+ (grade ≥4: BEAM
2.6% versus FEAM 6.0%) was higher in the FEAM group. This
observation may be traced back to the higher mucotoxicity
seen with the FEAM chemotherapy, and possibly related to
a different damage determined by this regimen on the enteric
mucosa, leading to enhanced disruption of the enteric/
blood barrier and easier translocation to the bloodstream of
Enterobacteriaceae and resident anaerobes, resulting in bac-
teremia and sepsis. In fact, the increased occurrence of SIEM+
in the FEAM group is attributable to more frequent isola-
tion of Gram-negative bacteria (mean isolates/patient: BEAM
.1 versus FEAM .19, P < .001), and in particular of Enterobac-
teriaceae (mean isolates/patient: BEAM .07 versus FEAM .13,
P = .002). This, in turn, may explain the higher mortality for
infection found in the FEAM group.
In favor of this hypothesis, an association between
transplant-related mortality and Gram-negative infections has
Table 4
Multivariate Analysis for Overall Survival, Progression-Free Survival, Cumulative Incidence of Relapse and Non-Relapse Mortality
OS HR (95% CI) P Value
Age at transplant Each year more 1.02 (1.009–1.03) <.001
Aggressive NHL Versus indolent NHL and HL 1.85 (1.346–2.543) <.001
ASCT after 1 salvage Versus upfront ASCT 1.495 (1.035–2.158) .032
ASCT after >1 salvage Versus upfront ASCT 2.89 (1.835–4.553) <.001
PR pre-ASCT Versus RD .374 (.256–.547) <.001
CR pre-ASCT Versus RD .152 (.102–.225) <.001
PFS HR (95% CI) P Value
Age at transplant Each year more 1.012 (1.004–1.02) .003
BM involvement at diagnosis Versus not 1.293 (1.039–1.61) .022
ASCT after >1 salvage Versus upfront/only 1 salvage 1.819 (1.401–2.362) <.001
Primary refractory Versus response at first line 1.478 (1.115–1.959) .007
PR pre-ASCT Versus RD .45 (.32–.631) <.001
CR pre-ASCT Versus RD .225 (.159–.317) <.001
Full-dose BCNU/fotemustine Versus reduced dose .757 (.581–.987) .04
FEAM-oriented center Versus BEAM-oriented or equally oriented 1.312 (1.039–1.656) .022
Relapse incidence SHR (95% CI) P Value
BM involvement at diagnosis Versus not 1.348 (1.071–1.696) .011
ASCT after >1 salvage Versus upfront/only 1 salvage 1.732 (1.296–2.315) <.001
Primary refractory Versus response at first line .718 (.523–.987) .041
PR pre-ASCT Versus RD .501 (.328–.767) .001
CR pre-ASCT Versus RD .28 (.185–.423) <.001
Reduced (<70%) BCNU/fotemustine dose Versus dose >70% 2.125 (1.488–3.034) <.001
FEAM-oriented center Versus BEAM oriented or equally oriented 1.308 (1.018–1.679) .035
NRM SHR (95% CI) P Value
Hodgkin lymphoma Versus others .266 (.106–.67) .005
ASCT after >1 salvage Versus upfront/only 1 salvage 2.293 (1.174–4.478) .015
Year of transplant Each year later .805 (.699–.927) .003
CR pre-ASCT Versus RD .313 (.167–.585) <.001
FEAM conditioning Versus BEAM 1.861 (1.023–3.385) .042
Center orientation: BEAM-oriented center (BEAM/FEAM ratio >75%); FEAM-oriented center (BEAM/FEAM ratio <25%); equally oriented center (BEAM/FEAM
ratio 25% to 75%.
SHR indicates subhazard ratio.
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also been described in a previous experience with FEAM [16].
Interestingly, an increased occurrence of bacteremias, but with
similar rate of overall infectious events, has been reported
for another more lipophilic substitute of BCNU (ie, thiotepa;
BEAM = 75, TEAM = 47; rate of infectious complications: BEAM
47% versus TEAM 53%; rate of sepsis/bacteremia: BEAM 13%
versus TEAM 32%) [23].
An alternative explanation could be the spread of multi-
resistant Gram-negative bacteria in Italian transplant centers
in more recent years [35]. However, in our data, the excess
isolates of Enterobacteriaceae observed with FEAM were con-
firmed restricting the analysis after 2011 (mean isolates/
patient: BEAM .07 versus FEAM .13, P = .009).
Our study has several limitations, the main one being
related to its design: retrospective cohort studies are con-
sidered at the lowest level of evidence in the hierarchy of
comparative research, with randomized controlled trials (RCTs)
being at the opposite end [36]. However, RCTs may not be
feasible in several situations and, owing to their interventional
nature, they are often restricted to a subset of the popula-
tion of interest, thereby affecting their external validity [36].
On the contrary, the main threaten for evidence gath-
ered from cohort studies is related to their internal validity,
due to risk of selection bias [37]. Although statistical tech-
niques have been developed to control for known imbalances
between the groups that are compared, they cannot obviate
for unknown factors that are neutralized by randomization.
However, if treatment allocation results from factors inde-
pendent of clinical decision, one might expect more easily
2 prognostically homogeneous groups, thereby allowing a
more reliable comparison between them. In our study, the
choice between BEAM and FEAM regimen resulted from
random variability of BCNU supply, differing among centers
and time periods. Such variability mirrored the logistic ability
of the centers to procure themselves with BCNU, which in
turn generally hindered the pharmacy attitude to find alter-
native ways to get BCNU (ie, foreign import). Indeed, in our
study, centers’ attitude was pretty evenly distributed between
those who were always able to get BCNU without major in-
terruptions using alternative channels (BEAM/FEAM ratio
>75%, n = 8), those who started to use steadily fotemustine
since they experienced the first difficulties to get BCNU
(BEAM/FEAM ratio <25%, n = 5), and those who switched
between the 2 owing to intermittent BCNU shortage (BEAM/
FEAM ratio 25% to 75%, n = 5). Therefore, most of the basal
characteristics were balanced between BEAM and FEAM,
without use of matching or other statistical techniques. The
only significant differences were year of transplant (later for
FEAM), Sorror score (higher in BEAM), use of radiotherapy
(more for BEAM), dose intensity of BCNU/fotemustine and
etoposide (higher in FEAM), and number of reinfused CD34+
cells × 106/kg (more for FEAM). Although it is expected that
some (5%) statistical tests will result significant owing to
chance, the observed imbalances likely reflect different poli-
cies for transplantation used in different centers, rather than
preferential allocation to one of the 2 groups. Center dis-
parities may confound results even in RCTs if the
randomization procedure does not account for center strat-
ification. In our analysis, we accounted for the center effect
by adding to the MVA a variable coding for center attitude
toward the 2 conditioning regimens. Interestingly, in the MVA
for PFS and RI, the variable coding for center attitude was more
informative than type of conditioning regimen and thus, in
the final model, the worse outcome related to FEAM condi-
tioning appears to be limited to FEAM-oriented centers
(BEAM/FEAM ratio <25%). Conversely, in the MVA for NRM,
type of conditioning emerged as a significant independent
predictor, while center attitude was not: thus, it is likely that
FEAM conditioning itself contributes to higher treatment-
related mortality. In our opinion, such interpretation appears
credible and is consistent with the other data, suggesting a
higher toxicity induced by substitution of fotemustine in the
BEAM regimen. However, given the discussed caveats and the
limited size effect observed, there is no absolute confidence
about this finding.
In conclusion, we compared 2 groups belonging to the
same cohort of patients and differing for one treatment vari-
able, aiming to add evidence to the increasing trend of
fotemustine substitution in the BEAM conditioning regi-
mens in lymphomas: our results exclude substantial
differences between the 2 treatments in terms of survival and
disease control. However, considering that no advantages of
FEAM over BEAM emerged, but rather concerns of higher tox-
icity did, fotemustine substitution in BEAM may not be
completely neutral, and thus its use in conditioning does not
appear justified when BCNU is available.
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